Overview

Investigation of the Superiority Effect of Orally Disintegrating Desmopressin Tablets to Placebo in Terms of Night Voids Reduction in Nocturia Adult Male Patients

Status:
Completed

Trial end date:
2012-01-01

Target enrollment:

Participant gender:

Summary

The purpose of this trial was to confirm/establish long-term safety and efficacy of desmopressin orally disintegrating tablets at dose levels of 50 μg and 75 μg and to further evaluate the safety of an efficacious higher dose level of 100 μg in males with nocturia.

Phase:

Phase 3

Details

Lead Sponsor:

Ferring Pharmaceuticals

Treatments:

Deamino Arginine Vasopressin